Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APRTX-005 is a preclinical-stage antisense oligonucleotide (ASO) candidate being developed by Aperture Therapeutics for the treatment of Parkinson's disease. As an ASO, the molecule is designed to bind to specific messenger RNA (mRNA) sequences to modulate the expression of a target protein involved in the pathogenesis of Parkinson's disease. While the specific molecular target of APRTX-005 is currently undisclosed by the developer, the drug is part of a pipeline focused on neurodegenerative and neurological disorders, utilizing oligonucleotide technology to address microglial-driven neuroinflammation or neuronal vulnerability. It is currently undergoing preclinical evaluation to support potential future clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APRTX-005.